VIATRIS INC. (VTRS) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.17%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -0.18×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 1.17% | Share-based compensation / revenue. Period ending 2026-06-30. $172.30M ÷ $14.69B × 100 ≈ 1.17% |
| Interest coverage · 12 months | -0.18× | Operating income ÷ reported interest expense. $-87.30M ÷ $480.00M ≈ -0.18× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 14.69B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 172.30M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -87.30M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 480.00M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $14.69B | $172.30M | $-87.30M | $480.00M | (m) | 1.17% | -0.18× | Reported |
| 2026-03-31 | (m) | $14.52B | $170.70M | $139.40M | $475.90M | (m) | 1.18% | 0.29× | Reported |
| 2025-12-31 | (m) | $14.25B | $177.70M | $-2.66B | $471.30M | (m) | 1.25% | -5.65× | Reported |
| 2025-09-30 | (m) | $14.08B | $160.60M | $-2.65B | $471.90M | (m) | 1.14% | -5.62× | Reported |
| 2025-06-30 | (m) | $14.07B | $157.00M | $-2.60B | $497.90M | (m) | 1.12% | -5.23× | Reported |
| 2025-03-31 | (m) | $14.28B | $154.60M | $-3.08B | $527.10M | (m) | 1.08% | -5.84× | Reported |
| 2024-12-31 | (m) | $14.69B | $146.10M | $10.10M | $550.00M | (m) | 0.99% | 0.02× | Reported |
| 2024-09-30 | (m) | $15.00B | $169.60M | $-264.60M | $570.70M | (m) | 1.13% | -0.46× | Reported |
| 2024-06-30 | (m) | $15.20B | $180.30M | $-38.80M | $566.60M | (m) | 1.19% | -0.07× | Reported |
| 2024-03-31 | (m) | $15.32B | $184.80M | $570.30M | $564.50M | (m) | 1.21% | 1.01× | Reported |
| 2023-12-31 | (m) | $15.39B | $180.70M | $766.20M | $573.10M | (m) | 1.17% | 1.34× | Reported |
| 2023-09-30 | (m) | $15.43B | $154.50M | $1.02B | $579.30M | (m) | 1.00% | 1.76× | Reported |
| 2023-06-30 | (m) | $15.56B | $140.50M | $1.13B | $591.00M | (m) | 0.90% | 1.91× | Reported |
| 2023-03-31 | (m) | $15.76B | $130.70M | $1.31B | $593.20M | (m) | 0.83% | 2.20× | Reported |
| 2022-12-31 | (m) | $16.22B | $116.40M | $1.61B | $592.40M | (m) | 0.72% | 2.73× | Reported |
| 2022-09-30 | $747.00M | $16.68B | $109.30M | $1.74B | $593.50M | 4.48% | 0.66% | 2.93× | Reported |
| 2022-06-30 | $724.20M | $17.14B | $105.20M | $1.54B | $592.20M | 4.23% | 0.61% | 2.59× | Reported |
| 2022-03-31 | $709.30M | $17.59B | $106.80M | $939.60M | $613.40M | 4.03% | 0.61% | 1.53× | Reported |
| 2021-12-31 | $751.10M | $17.81B | $111.20M | $-34.00M | $636.20M | 4.22% | 0.62% | -0.05× | Reported |
| 2021-09-30 | $638.70M | (m) | $118.10M | $-837.50M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $616.40M | (m) | $108.20M | $-843.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $625.00M | (m) | $92.50M | $-661.70M | $546.90M | (m) | (m) | -1.21× | Reported |
| 2020-12-31 | $555.10M | $11.82B | $79.20M | $-210.80M | $497.80M | 4.70% | 0.67% | -0.42× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $639.90M | $11.37B | $56.80M | $715.50M | $517.30M | 5.63% | 0.50% | 1.38× | Reported |
| 2018-12-31 | $704.50M | $11.27B | $-3.30M | $905.60M | $542.30M | 6.25% | -0.03% | 1.67× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |